The genetic puzzle behind endometriosis—a condition affecting one in ten women worldwide—has long frustrated researchers and patients alike. Despite causing debilitating pain and fertility issues, the molecular drivers of this chronic inflammatory disease have remained largely mysterious, limiting both diagnostic precision and therapeutic options.
This landmark genomic investigation analyzed DNA from 1.4 million women across diverse ancestries, including over 105,000 endometriosis cases. The research identified 80 distinct chromosomal regions linked to endometriosis susceptibility, with 37 representing entirely new genetic associations. Five of these regions also influence adenomyosis risk, suggesting shared pathways between related gynecological conditions. Beyond simple genetic mapping, the team pinpointed specific DNA variants likely responsible for over 50 of these associations, moving closer to actionable molecular targets.
Integrating genomic data with tissue-specific gene expression, protein levels, and epigenetic modifications revealed endometriosis primarily disrupts cellular differentiation pathways alongside immune system regulation and tissue remodeling processes. This multi-layered analysis supports longstanding hypotheses about endometriosis involving hormonal dysregulation and chronic inflammation, now backed by concrete molecular evidence.
The clinical implications extend beyond basic biology. Computational drug repurposing analyses identified existing medications—currently used for breast cancer treatment, contraception, and preventing preterm birth—as potential endometriosis therapies. The study also revealed how genetic endometriosis risk interacts with symptoms like abdominal pain, anxiety, and migraines, potentially explaining why this condition often clusters with other chronic pain disorders. While translating these genetic insights into clinical practice will require years of validation studies, this comprehensive molecular map provides the most detailed roadmap yet for developing precision treatments for millions of affected women.